| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200401-093OC |
| P698 | PubMed publication ID | 15229094 |
| P2093 | author name string | Wouter Meersseman | |
| Alexander Wilmer | |||
| Eric Van Wijngaerden | |||
| Eric Verbeken | |||
| Willy E Peetermans | |||
| Stefaan J Vandecasteele | |||
| P433 | issue | 6 | |
| P921 | main subject | invasive aspergillosis | Q3625278 |
| P304 | page(s) | 621-625 | |
| P577 | publication date | 2004-06-30 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Invasive aspergillosis in critically ill patients without malignancy | |
| P478 | volume | 170 |
| Q36864397 | A 10-year study reveals clinical and laboratory evidence for the 'semi-invasive' properties of chronic pulmonary aspergillosis. |
| Q37192161 | A Case of Acute Cerebral Aspergillosis Complicating Influenza A/H1N1pdm 2009 |
| Q51035901 | A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. |
| Q36439253 | A validated clinical approach for the management of aspergillosis in critically ill patients: ready, steady, go! |
| Q83186061 | Allergic bronchopulmonary aspergillosis in a patient with chronic obstructive pulmonary disease |
| Q46600233 | Anidulafungin: a new echinocandin for the treatment of mycosis |
| Q43449387 | Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin |
| Q91960710 | Are workers from waste sorting industry really protected by wearing Filtering Respiratory Protective Devices? The gap between the myth and reality |
| Q34559978 | Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes |
| Q37785542 | Aspergillosis: nosocomial or community-acquired? |
| Q49546197 | Aspergillus in airway material : Ignore or treat? |
| Q33851319 | Aspergillus species in indoor environments and their possible occupational and public health hazards |
| Q36999971 | Aspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study |
| Q35530416 | Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study |
| Q42646662 | Beta-glucan-CRM197 conjugates as candidates antifungal vaccines |
| Q89509794 | Blood Aspergillus PCR: The Good, the Bad, and the Ugly |
| Q37115801 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| Q40107589 | Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer |
| Q36538804 | Cavitary pulmonary disease. |
| Q46396373 | Cerebral aspergillosis in the critically ill: two cases of successful medical treatment |
| Q49604618 | Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review. |
| Q37480190 | Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species |
| Q84304099 | Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases |
| Q35567147 | Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study |
| Q37479561 | Clinical findings in 19 cases of invasive pulmonary aspergillosis with liver cirrhosis |
| Q54196298 | Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay. |
| Q41998776 | Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients |
| Q36478542 | Clinical risk factors and bronchoscopic features of invasive aspergillosis in intensive care unit patients |
| Q38221673 | Current challenges in the microbiological diagnosis of invasive aspergillosis |
| Q37319452 | Defining, treating and preventing hospital acquired pneumonia: European perspective |
| Q92637744 | Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing |
| Q42531170 | Detection, identification, and distribution of fungi in bronchoalveolar lavage specimens by use of multilocus PCR coupled with electrospray ionization/mass spectrometry |
| Q36348556 | Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. |
| Q91632153 | Disseminated aspergillosis in an immunocompetent patient treated with corticosteroids: value of PCR for diagnosis |
| Q42111814 | Disseminated enteroinvasive aspergillosis in a critically ill patient without severe immunocompromise |
| Q36886708 | Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study |
| Q44397527 | Early diagnosis of invasive fungal infections caused by Aspergillus and other emerging mycelial fungi |
| Q40794362 | Editorial: Advances in Aspergillus fumigatus Pathobiology |
| Q39565084 | Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis |
| Q110696307 | Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance |
| Q90618668 | Environmental Isolates of Multi-Azole-Resistant Aspergillus spp. in Southern Italy |
| Q37864427 | Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature |
| Q49587328 | Epidemiology of fungal infections in China |
| Q35131913 | Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes |
| Q34688953 | Evaluation of MycAssay™ Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer |
| Q40948260 | Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. |
| Q90382196 | Fatal Disseminated Aspergillosis in a Patient with Systemic Lupus Erythematosus |
| Q54233900 | Fungal infections in adult patients on extracorporeal life support. |
| Q37058527 | Fungal infections in intensive care unit: challenges in diagnosis and management |
| Q44790540 | Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi |
| Q37632011 | Galactomannan antigen assay from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in intensive care units patients |
| Q39504883 | Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates. |
| Q36405499 | Genomics of Aspergillus fumigatus |
| Q42798782 | Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity |
| Q36287958 | High-resolution computed tomography (HRCT) of lung infections in non-AIDS immunocompromised patients |
| Q26999448 | How to manage aspergillosis in non-neutropenic intensive care unit patients |
| Q38215670 | Identification and management of invasive mycoses in internal medicine: a road-map for physicians |
| Q40088340 | Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation |
| Q37677599 | Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults |
| Q36587261 | Immunological aspects of Candida and Aspergillus systemic fungal infections |
| Q34129471 | Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis |
| Q42382713 | Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit |
| Q40248126 | In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. |
| Q28542402 | In vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosis |
| Q43759764 | Incidence of pulmonary aspergillosis and correlation of conventional diagnostic methods with nested PCR and real-time PCR assay using BAL fluid in intensive care unit patients. |
| Q36934706 | Infections in chronic lung diseases |
| Q36906082 | Invasive Aspergillus infections in hospitalized patients with chronic lung disease |
| Q40604174 | Invasive Pulmonary Aspergillosis with Disseminated Infection in Immunocompetent Patient. |
| Q30389749 | Invasive aspergillosis after pandemic (H1N1) 2009. |
| Q57173998 | Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study |
| Q35528678 | Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. |
| Q44610230 | Invasive aspergillosis in the ICU: an emerging disease |
| Q40092968 | Invasive aspergillosis successfully treated by combined antifungal therapy and immunosuppressive monotherapy two months following heart transplantation. |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q38151663 | Invasive fungal infections |
| Q36540976 | Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q37583916 | Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. |
| Q44590211 | Invasive mycoses and trauma |
| Q40494601 | Invasive pulmonary aspergillosis complicating septic shock |
| Q33719459 | Invasive pulmonary aspergillosis in an immunocompetent patient with severe dengue fever |
| Q37152418 | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease |
| Q51176004 | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease. |
| Q33271183 | Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series |
| Q43631437 | Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study |
| Q46106820 | Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis |
| Q36307784 | Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria |
| Q33391938 | Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. |
| Q24811601 | Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome |
| Q55126951 | Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole. |
| Q36267587 | Laboratory diagnosis of invasive aspergillosis. |
| Q38164008 | Major discrepancies between clinical and postmortem diagnoses in critically ill cancer patients: Is autopsy still useful? |
| Q37294689 | Management of invasive aspergillosis in patients with COPD: rational use of voriconazole. |
| Q36087577 | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients |
| Q49166015 | Mechanisms, clinically curative effects, and antifungal activities of cinnamon oil and pogostemon oil complex against three species of Candida |
| Q51187346 | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. |
| Q47136905 | Monitoring of clinical strains and environmental fungal aerocontamination to prevent invasive aspergillosis infections in hospital during large deconstruction work: a protocol study |
| Q35575320 | Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients |
| Q33610419 | Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome |
| Q33552719 | NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model |
| Q54217644 | Overview of Commercially Available PCR Assays for the Detection of Aspergillus spp. DNA in Patient Samples. |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q37538782 | Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis |
| Q36505281 | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. |
| Q35385554 | Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model |
| Q36276845 | Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q33757912 | Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. |
| Q35076830 | Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. |
| Q57569130 | Post-surgical invasive aspergillosis: An uncommon and under-appreciated entity |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q97427835 | Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment |
| Q36344062 | Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study. |
| Q40417418 | Rapidly progressing dual infection with Aspergillus and Rhizopus: when soil inhabitants become deadly invaders |
| Q64131314 | Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: una visión multidisciplinar |
| Q24606804 | Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study |
| Q36633947 | Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study |
| Q52570071 | Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population. |
| Q92321133 | Severe Fever with Thrombocytopenia Syndrome Complicated with Pseudomembranous Aspergillus Tracheobronchitis in a Patient without Apparent Risk Factors for Invasive Aspergillosis |
| Q55281032 | Sputum signatures for invasive pulmonary aspergillosis in patients with underlying respiratory diseases (SPARED): study protocol for a prospective diagnostic trial. |
| Q44613553 | Successful management of Aspergillus liver abscess in a patient with necrotizing fasciitis |
| Q39653392 | Successful pneumonectomy for invasive pulmonary aspergillosis and advanced non-small cell-lung cancer |
| Q51748116 | Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals |
| Q24303676 | The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses |
| Q35196866 | The application of laser microdissection in molecular detection and identification of aspergillus fumigatus from murine model of acute invasive pulmonary aspergillosis |
| Q28387394 | The immune interplay between the host and the pathogen in Aspergillus fumigatus lung infection |
| Q54321109 | The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD). |
| Q42382708 | The role of galactomannan testing to diagnose invasive pulmonary aspergillosis in critically ill patients |
| Q37544911 | Tissue penetration of antifungal agents. |
| Q61832641 | Update on invasive fungal infections: the last two years |
| Q37860559 | Update on invasive mycoses by filamentous fungi in critically ill patients. |
| Q36098515 | Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts |
| Q35331642 | Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid |
| Q85178759 | Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease |
| Q41791143 | Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. |
| Q80737382 | [Bronchopulmonary aspergillosis infections in the non-immunocompromised patient] |
| Q84752659 | [Community-acquired pneumonia] |
| Q45942598 | [Current status of invasive fungal infections. New diagnostic techniques and antifungal agents]. |
| Q81193460 | [Epidemiology of and risk factors for invasive aspergillosis in nonneutropenic patients] |
| Q79385633 | [Invasive pulmonary aspergillosis in the non-neutropenic critical patient: future challenges] |
| Q91901915 | [Management of nosocomial pneumonia-state of the art] |
Search more.